Vanadis NIPT — New NIPT Provider for Clinics and Regions

Switch to Vanadis NIPT — iLab’s NIPT Offering

iLab is your Swedish partner for next-generation NIPT. We offer Vanadis® NIPT — the only Swedish-developed NIPT platform on the international market — analysed at our laboratory in Gothenburg, Sweden.

Looking for a New NIPT Provider?

iLab offers Vanadis® NIPT — a groundbreaking Swedish invention delivering reliable, high-quality non-invasive prenatal testing. We are your partner if your clinic or region is seeking a new NIPT provider that guarantees:

  • Nordic data processing — all analysis is performed in Sweden, on a European platform. No data is transferred to non-European actors.
  • No genetic sequencing — neither the fetus nor the mother’s DNA is decoded or stored. Complete data privacy.
  • Full GDPR compliance — patient data stays within the Nordic region
  • Seamless lab portal integration — maintain your existing workflow without disruption
  • Documented clinical performance — validated on >10,000 Swedish patients

About the Vanadis NIPT Technology

Vanadis® NIPT is a patented method based on Rolling Circle Replication (RCR), an elegant DNA amplification technique that requires no sequencing. The method was developed by inventor Olle Ericsson and launched in 2018 by Revvity (formerly PerkinElmer). The platform is today deployed at leading university hospitals in the Nordic region and Europe, including Helsinki University Hospital (HUS). The technical foundation is described in an early validation by Dahl et al. (2018) [1].

The Vanadis method counts DNA fragments, but does not sequence them. This means:

  • No individual genetic information is decoded or stored for either the mother or the fetus
  • Analysis takes place entirely in Sweden, at iLab in Gothenburg
  • Full GDPR compliance without exception

Scope of Analysis

Vanadis NIPT analyses the clinically recommended conditions in accordance with established guidelines:

  • Trisomy 21 (Down syndrome)
  • Trisomy 18 (Edwards syndrome)
  • Trisomy 13 (Patau syndrome)
  • Sex chromosome abnormalities — available as an optional add-on

Clinical Data That Stands Out

Vanadis NIPT has been validated in multiple independent international studies and consistently performs well compared to older platforms.

In a comparative study published in the American Journal of Obstetrics and Gynecology (Conotte et al., 2022) [2] comparing Harmony® and Vanadis® across 900 patients:

  • Vanadis sensitivity: 98.1% vs Harmony 90.6%
  • Vanadis specificity: 99.64% vs Harmony 96.92%
  • Vanadis no-call rate: 0.22% vs Harmony 3.22% (first run)

In a large real-world study of 8,160 patients (Saidel et al., 2023) [3], the Vanadis system demonstrated:

  • No-call rate: 0.07% (7 per 10,000)
  • Overall sensitivity: 98%
  • Specificity: >99%

iLab’s own cohort of over 10,000 patients tested in Sweden confirms these results. These data are awaiting publication.

In 2023, 15% of all births in the Västra Götaland region were screened with Vanadis NIPT through iLab. The platform has been shown to perform well at high BMI, in twin pregnancies and IVF pregnancies, and does not require a minimum fetal fraction of ≥4% as older methods do.

Quality and Accreditation

iLab actively operates in accordance with ISO 15189 — the international standard for medical laboratories — and is in the final stages of its accreditation process. We expect to complete our first accreditation assessment within the coming months. This means that clinics and regions choosing iLab are choosing a laboratory with documented quality systems and full transparency.

For Clinics and Healthcare Providers

We work with private and public antenatal clinics, ultrasound clinics and hospitals wishing to offer NIPT to their patients. We offer:

  • Simple ordering routines via our integrated lab portal
  • Support for sample collection and logistics
  • Turnaround time 3–10 working days after receipt at the laboratory
  • Competitive pricing
  • Consultation support for clinical interpretation
  • Responsible physician: Simon Pålsson, M.D., Ph.D.
  • Laboratory Director: Professor Massoud Houshmand, Ph.D., Medical Genetics, University of Gothenburg

For Regions Procuring NIPT

iLab is a suitable provider for regions seeking to procure NIPT analysis with requirements for:

  • European data platform — no data transferred to non-European actors
  • No genetic sequencing — no exposure of genetic information
  • Laboratory working towards ISO 15189 accreditation
  • Documented clinical performance with >10,000 analysed Swedish patients
  • Local presence in Sweden (Gothenburg) with a shorter supply chain
  • Competitive pricing and transparent contract terms
  • Transparent reporting and quality assurance

Published Studies on Vanadis NIPT

Below is a list of peer-reviewed publications evaluating the performance and clinical application of the Vanadis® NIPT platform:

  1. Dahl F, et al. Imaging single DNA molecules for high precision NIPT. Scientific Reports 2018;8:4549. doi:10.1038/s41598-018-22606-0
  2. Conotte S, El Kenz H, De Marchin J, Jani JC. Cell-free DNA analysis for noninvasive examination of trisomy: comparing 2 targeted methods. Am J Obstet Gynecol 2022;227(3):539–541. doi:10.1016/j.ajog.2022.05.024
  3. Saidel ML, Ananth U, Rose D, Farrell C. Non-invasive prenatal testing with rolling circle amplification: Real-world clinical experience in a non-molecular laboratory. J Clin Lab Anal 2023;37(6):e24870. doi:10.1002/jcla.24870
  4. Gormus U, Chaubey A, Shenoy S, et al. Assessment and Clinical Utility of a Non-Next-Generation Sequencing-Based Non-Invasive Prenatal Testing Technology. Curr Issues Mol Biol 2021;43(2):958–964. doi:10.3390/cimb43020068
  5. Pooh RK, Masuda C, Matsushika R, et al. Clinical Validation of Fetal cfDNA Analysis Using Rolling-Circle-Replication and Imaging Technology in Osaka (CRITO Study). Diagnostics (Basel) 2021;11(10):1837. doi:10.3390/diagnostics11101837
  6. Pavanello L, et al. Cell-free DNA screening for fetal aneuploidy using the rolling circle method: A step towards non-invasive prenatal testing simplification. See reference list
  7. Cerreta V, Musti MA, Simonazzi G, et al. Screening for major aneuploidies at 10 weeks of gestation in an unselected population: comparing the combined test to the NIPT with rolling-circle replication (SAPERER study). Eur J Obstet Gynecol Reprod Biol 2026;321:115035. doi:10.1016/j.ejogrb.2026.115035

A comprehensive list of scientific studies is also available at babyscreen.se/vetenskapliga-studier/.

Contact Us

Interested in switching to Vanadis® NIPT, or would you like to know more about how we can support your operations? Contact us and we will tell you more about the onboarding process and how we can tailor the service to your needs.

Go to contact page →